{"acquisitions":[],"changes":[],"country":"US","description":"Crossbow Therapeutics develops T-cell receptor mimic antibodies that target intracellular cancer antigens previously inaccessible to monoclonal therapy. It serves oncology partners and patients with cancers driven by intracellular tumor antigens like MAGE, NY-ESO, and HPV proteins. The TCRm platform extends antibody-style precision into the part of the proteome conventional mAbs cannot reach.","domain":"crossbowrx.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.365635,"lng":-71.104002,"location":"Cambridge MA","multiples":[],"name":"Crossbow Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":77000000,"connectionsAmong":[],"currency":"USD","date":"2026-03-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"crossbowrx-com-2026-03-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"crossbowrx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"crossbowrx.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://crossbowrx.com"},{"fact":"description","publisher":"crossbowrx.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://crossbowrx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":120000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}